In that trial, vinflunine did not reach statistical significance in improving mOS compared to BSC in the intention-to-treat (ITT) analysis (6.9 months vs. 4.3 months), although the use of vinflunine was independently correlated with improved survival in multivariable analysis [ 48 , 49 ].
← all excerpts
Systemic treatment for advanced urothelial cancer: an update on recent clinical trials and current treatment options.
1
—
—